
Julius Wehrle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/724636/publications.pdf Version: 2024-02-01



ППППС М/ЕНDLE

#	Article	IF	CITATIONS
1	Oncogenic JAK2 ^{V617F} causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Science Translational Medicine, 2018, 10, .	5.8	166
2	Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. Nature Medicine, 2021, 27, 1806-1817.	15.2	79
3	Early assessment of circulating tumor DNA after curativeâ€intent resection predicts tumor recurrence in earlyâ€stage and locally advanced nonâ€smallâ€cell lung cancer. Molecular Oncology, 2022, 16, 527-537.	2.1	42
4	Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience. JCO Precision Oncology, 2018, 2, 1-16.	1.5	41
5	Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. Cancers, 2021, 13, 1151.	1.7	27
6	Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma. JCO Precision Oncology, 2020, 4, 20-31.	1.5	19
7	Bisulfite-free epigenomics and genomics of single cells through methylation-sensitive restriction. Communications Biology, 2021, 4, 153.	2.0	17
8	Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment. British Journal of Haematology, 2018, 182, 830-842.	1.2	16
9	Predicting persistence of atopic dermatitis in children using clinical attributes and serum proteins. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1158-1172.	2.7	16
10	Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia. Annals of Hematology, 2020, 99, 1551-1560.	0.8	15
11	A novel role for nuclear factor-erythroid 2 in erythroid maturation by modulation of mitochondrial autophagy. Haematologica, 2016, 101, 1054-1064.	1.7	13
12	Ponatinib: A Third-Generation Inhibitor for the Treatment of CML. Recent Results in Cancer Research, 2018, 212, 109-118.	1.8	10
13	Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy. Leukemia Research, 2020, 98, 106454.	0.4	8
14	Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management. Diagnostics, 2020, 10, 550.	1.3	8
15	Clonal hematopoiesis of indeterminate potential in older patients having received an allogeneic stem cell transplantation from young donors. Bone Marrow Transplantation, 2020, 55, 665-668.	1.3	7
16	Genotyping of Circulating Free DNA Enables Monitoring of Tumor Dynamics in Synovial Sarcomas. Cancers, 2022, 14, 2078.	1.7	6
17	The transcription factor NFE2 enhances expression of the hematopoietic master regulators SCL/TAL1 and GATA2. Experimental Hematology, 2020, 87, 42-47.e1.	0.2	4
18	The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia. Experimental Hematology, 2017, 55, 76-85.e3.	0.2	3

JULIUS WEHRLE

#	Article	IF	CITATIONS
19	Stringent Base Specific and Optimization-Free Multiplex Mediator Probe ddPCR for the Quantification of Point Mutations in Circulating Tumor DNA. Cancers, 2021, 13, 5742.	1.7	3
20	Monosomy 7 As the Initial Hit Followed By Sequential Acquisition of SETBP1 and ASXL1 Driver Mutations in Childhood Myelodysplastic Syndromes. Blood, 2018, 132, 105-105.	0.6	2
21	Targeted next-generation sequencing of circulating free DNA enables non-invasive tumor detection in myxoid liposarcomas. Molecular Cancer, 2022, 21, 50.	7.9	2